ES2483896T3 - Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen - Google Patents

Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen Download PDF

Info

Publication number
ES2483896T3
ES2483896T3 ES03785958.4T ES03785958T ES2483896T3 ES 2483896 T3 ES2483896 T3 ES 2483896T3 ES 03785958 T ES03785958 T ES 03785958T ES 2483896 T3 ES2483896 T3 ES 2483896T3
Authority
ES
Spain
Prior art keywords
breast cancer
hydroxy tamoxifen
prevention
medication
sine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03785958.4T
Other languages
English (en)
Inventor
Dominique Salin-Drouin
Jacques Wepierre
Philippe Rouanet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins Healthcare Luxembourg SARL
Original Assignee
Besins Healthcare Luxembourg SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Luxembourg SARL filed Critical Besins Healthcare Luxembourg SARL
Application granted granted Critical
Publication of ES2483896T3 publication Critical patent/ES2483896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Medicamento para uso para la prevención de cáncer de seno en un paciente en mayor riesgo de desarrollar cáncer de seno, en donde dicho medicamento es una composición hidroalcohólica para administración percutánea que contiene 4-hidroxi tamoxifen, miristato de isopropilo como potenciador de la penetración, un vehículo acuoso, un vehículo alcohólico y un agente gelificante, en donde el 4-hidroxi tamoxifen es para administrado en una cantidad de aproximadamente 0.25 a 2.0 mg/seno, preferiblemente aproximadamente 0.5 a 1.0 mg/seno por día, en donde dicho incremento del riesgo para desarrollar cáncer de seno es seleccionado de la historia familiar de cáncer de seno; historia personales de cáncer de seno; detección por biopsia de seno previa de hiperplasia atípica; irradiación del seno previa; factores de riesgo genéticos seleccionados de BRCA1, BRCA2, ATM, CHEK-2 y las mutaciones de p53; partos retrasados hasta después de la edad de 30 años

Description

imagen1

Claims (1)

  1. imagen1
ES03785958.4T 2003-04-01 2003-12-15 Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen Expired - Lifetime ES2483896T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
US458963P 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
ES2483896T3 true ES2483896T3 (es) 2014-08-08

Family

ID=33131847

Family Applications (3)

Application Number Title Priority Date Filing Date
ES03785958.4T Expired - Lifetime ES2483896T3 (es) 2003-04-01 2003-12-15 Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
ES08103007.4T Expired - Lifetime ES2456957T3 (es) 2003-04-01 2003-12-15 Tratamiento de cáncer de seno con 4-hidroxitamoxifen
ES08103014.0T Expired - Lifetime ES2456958T3 (es) 2003-04-01 2003-12-15 Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES08103007.4T Expired - Lifetime ES2456957T3 (es) 2003-04-01 2003-12-15 Tratamiento de cáncer de seno con 4-hidroxitamoxifen
ES08103014.0T Expired - Lifetime ES2456958T3 (es) 2003-04-01 2003-12-15 Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen

Country Status (12)

Country Link
US (2) US7704516B2 (es)
EP (3) EP1608353B1 (es)
JP (1) JP5490346B2 (es)
AU (1) AU2003294973B2 (es)
CA (1) CA2519980C (es)
ES (3) ES2483896T3 (es)
HK (2) HK1086193A1 (es)
IL (1) IL170807A (es)
MX (1) MXPA05010597A (es)
NO (1) NO333805B1 (es)
NZ (1) NZ542499A (es)
WO (1) WO2004087123A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296757A1 (en) * 2002-12-18 2004-07-09 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
DK1572178T3 (da) * 2002-12-18 2006-09-11 Besins Int Lab Behandling af mastalgi med 4-hydroxytamoxifen
EP1608353B1 (en) * 2003-04-01 2014-04-30 Besins Healthcare Luxembourg SARL Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
RU2357726C2 (ru) * 2004-03-22 2009-06-10 Лаборатуар Безен Энтернасьональ Лечение и профилактика доброкачественной опухоли груди 4-гидрокситамоксифеном
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
AU2005293712B2 (en) * 2004-10-14 2011-04-21 Besins Healthcare Luxembourg Sarl 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US9459267B2 (en) 2014-05-12 2016-10-04 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen and metabolites thereof by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
WO2016031342A1 (ja) * 2014-08-27 2016-03-03 東洋紡株式会社 低誘電接着剤組成物
US10278976B2 (en) 2014-12-12 2019-05-07 Mira Dx, Inc. Methods for treating or preventing cancer in a KRAS-variant patient and for diagnosing risk of developing multiple primary breast tumors
EP4029950A1 (en) * 2016-04-29 2022-07-20 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors
CN116832020A (zh) 2017-09-11 2023-10-03 阿托萨治疗学公司 制备和使用内昔芬的方法
US20210009865A1 (en) 2018-03-07 2021-01-14 Toagosei Co., Ltd. Adhesive composition, and adhesive layer-equipped layered product using same
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (es) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ATE200978T1 (de) * 1996-03-29 2001-05-15 S W Patentverwertungs Ges M B KOSMETIKUM BZW. KOSMETIKZUSAMMENSETZUNG ZUR GLÄTTUNG UND STRAFFUNG DER HAUT BEI GESTÖRTEM UNTERHAUT-BINDE-FETTGEWEBE, INSBESONDERE BEI DER ßCELLULITEß
JP2001527037A (ja) 1997-12-23 2001-12-25 ヘキサル アーゲー Ｚ−４−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
AU778475B2 (en) 1999-12-16 2004-12-09 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
ATE439829T1 (de) * 2001-12-07 2009-09-15 Besins Int Belgique Gel oder lísung enthaltend dihydrotestosterone, deren herstellungsverfahren und verwendung
DK1572178T3 (da) * 2002-12-18 2006-09-11 Besins Int Lab Behandling af mastalgi med 4-hydroxytamoxifen
AU2003296757A1 (en) * 2002-12-18 2004-07-09 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1608353B1 (en) 2003-04-01 2014-04-30 Besins Healthcare Luxembourg SARL Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
NZ542499A (en) 2008-10-31
US20090186944A1 (en) 2009-07-23
NO333805B1 (no) 2013-09-16
JP2006514967A (ja) 2006-05-18
JP5490346B2 (ja) 2014-05-14
ES2456958T3 (es) 2014-04-24
HK1119950A1 (en) 2009-03-20
CA2519980A1 (en) 2004-10-14
EP1952810B1 (en) 2014-01-08
IL170807A (en) 2014-08-31
EP1608353A1 (en) 2005-12-28
NO20054526L (no) 2005-09-30
US8475814B2 (en) 2013-07-02
AU2003294973B2 (en) 2010-05-13
WO2004087123A1 (en) 2004-10-14
EP1941871B1 (en) 2014-01-08
AU2003294973A1 (en) 2004-10-25
EP1941871A1 (en) 2008-07-09
HK1086193A1 (en) 2006-09-15
US7704516B2 (en) 2010-04-27
CA2519980C (en) 2012-04-10
US20050031695A1 (en) 2005-02-10
EP1952810A1 (en) 2008-08-06
EP1608353B1 (en) 2014-04-30
ES2456957T3 (es) 2014-04-24
MXPA05010597A (es) 2006-03-09

Similar Documents

Publication Publication Date Title
ES2483896T3 (es) Prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
Hirakawa et al. Surgical site infection in clean-contaminated head and neck cancer surgery: risk factors and prognosis
Emiroglu et al. The effects of curcumin on wound healing in a rat model of nasal mucosal trauma
Buchsel et al. Polyvinylpyrrolidone–sodium hyaluronate gel (Gelclair®): A bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions
BRPI0607168A2 (pt) terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
Kini et al. An unusual occurrence of epidermoid cyst in the buccal mucosa: a case report with review of literature
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
PE20070432A1 (es) Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) o sus sales
BRPI0411079A (pt) composições farmacêuticas compreendendo atorvastatina, fabricadas sem granulação
Piraccini et al. Ciclopirox hydroxypropyl chitosan (HPCH) nail lacquer: a review of its use in onychomycosis
JP2006514967A5 (es)
ATE376824T1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
JP2006514949A5 (es)
Khan et al. Impact of gold nanoparticles on colon cancer treatment and diagnosis
AR050255A1 (es) Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas
ATE499378T1 (de) Anthracyclinderivate
US20060013862A1 (en) Onychomycosis: a new process for cure
CA2706577A1 (en) Use of avicins to deliver therapeutic and diagnostic agents
PE20070701A1 (es) Terapia contra el cancer con estrogeno
Kravchenko et al. PHARMACOKINETIC SUBSTANTIATION OF THE THERAPEUTIC EFFICACY OF ANTISEPTIC PREPARATION CYDIPOL IN TREATMENT OF PROSTATITIS
AR028611A1 (es) Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa
ES2308744T3 (es) Utilizacion del gluconato de zinc para el tratamiento de hidradenita supurada.
Goosmann et al. Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations